Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC - Free Report) in a research report sent to investors on Friday morning. The firm issued a hold rating on the biopharmaceutical company's stock.

A number of other equities analysts have also commented on RVNC. Mizuho decreased their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating for the company in a research note on Tuesday, December 10th. Needham & Company LLC reissued a "hold" rating on shares of Revance Therapeutics in a research note on Friday, November 8th. HC Wainwright reaffirmed a "neutral" rating and set a $6.60 target price on shares of Revance Therapeutics in a research note on Friday, November 8th. Finally, Barclays reiterated an "equal weight" rating and issued a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, Revance Therapeutics currently has a consensus rating of "Hold" and an average price target of $8.96.

Revance Therapeutics Stock Up 0.7 %

Shares of NASDAQ RVNC traded up $0.02 during mid-day trading on Friday, hitting $3.09. 3,458,729 shares of the company traded hands, compared to its average volume of 2,819,810. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $9.74. The stock has a market capitalization of $322.57 million, a price-to-earnings ratio of -1.60 and a beta of 0.81. The business has a 50 day moving average of $4.38 and a two-hundred day moving average of $4.47.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to the consensus estimate of $67.73 million. As a group, research analysts anticipate that Revance Therapeutics will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Revance Therapeutics

Several institutional investors have recently made changes to their positions in the company. Certuity LLC bought a new position in Revance Therapeutics during the second quarter valued at approximately $26,000. Vanguard Personalized Indexing Management LLC bought a new stake in Revance Therapeutics in the second quarter worth $33,000. Hsbc Holdings PLC acquired a new position in Revance Therapeutics during the second quarter worth $38,000. Nisa Investment Advisors LLC raised its holdings in Revance Therapeutics by 2,167.5% during the second quarter. Nisa Investment Advisors LLC now owns 18,911 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 18,077 shares in the last quarter. Finally, FORA Capital LLC bought a new position in Revance Therapeutics during the third quarter valued at about $54,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.